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ABSTRACT 
Background: Biomarker has a role in diagnosis and risk stratification of ischemic heart 
disease patients. Troponin has become the reference biomarker for acute myocardial 
infarction (AMI). However, some other biomarkers have benefit on prognostic value, such as 
C-Reactive Protein (CRP). Six-minute walk test (6MWT) could be performed to assess 
functional capacity in patients with heart disease.  
Aim: To assess the correlation between hsCRP and hsTroponin I with 6-minute walk 
distance (6MWD) in AMI patients. 
Method: This is an observational analytic study with prospective cohort design, conducted 
in August-September 2018. The subjects were AMI patients at Dr. Moewardi district general 
hospital, Surakarta. The hsCRP and hsTroponin I sampling was carried out on admission. 
6MWT was performed before discharge. Statistical analysis was performed to assess the 
correlation. Then the ROC curve was used to determine the cut-off point, sensitivity and 
specificity.  
Result: 6MWD of 40 subjects was divided into 2 groups based on the mean distance (<378 
m and ≥378 m). There was a significant negative correlation between hsCRP and 6MWD (r 
=-0.475, p =0.002), but no significant correlation between hsTroponin I and 6MWD (r =-
0.048, p = 0.244). However, hsCRP together with hsTroponin I have a significant correlation 
with 6MWD (r =0.491, p =0.006). Using the ROC curve, obtained AUC of 0.725 and a cut-off 
point of 0.555 mg/l, as well as a sensitivity of 69.6% and specificity of 88.2% 
Conclusion: There was a significant negative relationship between hsCRP and 6MWD, but 
no significant relationship between hsTroponin I with 6MWD.HsCRP together with 
hsTroponin I have a significant correlation with 6MWD in AMI. 
 














Latar Belakang: Biomarka memegang peranan dalam diagnosis dan stratifikasi risiko 
pada pasien dengan penyakit jantung iskemik. Troponin  menjadi biomarka rujukan pada 
infark miokard akut (IMA). Namun terdapat beberapa biomarka yang  bisa memberi nilai 
tambah dalam informasi prognostik, salah satunya adalah C-reactive protein (CRP). Six-
minute walk test (6MWT) dapat dilakukan untuk menilai kapasitas fungsional pada pasien 
dengan penyakit jantung. 
Tujuan: Untuk mengetahui hubungan antara kadar hsCRP dan hsTroponin I dengan jarak 
tempuh 6MWT pada pasien IMA. 
Metode: Penelitian ini adalah studi observasional analitik dengan desain kohort prospektif, 
dilakukan pada bulan Agustus–September 2018. Subyeknya adalahpenderita IMA di RSUD 
Dr.Moewardi, Surakarta. Pengambilan sampel hsCRP dan hsTroponin I dilakukan saat 
pasien masuk IGD. 6MWT dilakukan sebelum pasien pulang. Analisis statistik dilakukan 
untuk menilai korelasi dengan uji korelasi ganda, kemudian dihitung cut-off point, 
sensitivitas, serta spesifisitas dengan menggunakan kurva ROC. 
Hasil: Dari 40 subyek diperoleh jarak tempuh 6MWT yang dibagi 2 kelompok berdasarkan 
rerata, yaitu< 378 m dan ≥ 378 m. HsCRP dan jarak tempuh 6MWT memiliki hubungan 
negatif yang bermakna (r = -0.475, p = 0.002), sedangkan hsTroponin I tidak memiliki 
hubungan bermakna dengan jarak tempuh 6MWT (r = -0.048, p = 0.244). Namun, hsCRP 
dan hsTroponin I secara bersama-sama berhubungan dengan jarak tempuh 6MWT secara 
bermakna (r = 0.491, p = 0.006). Dengan kurva ROC, didapatkan AUC 0.725 dan cut-off 
point 0.555 mg/l, serta sensitivitas 69.6% dan spesifisitas 88.2%. 
Kesimpulan: Terdapat hubungan negatif yang bermakna antara kadar hsCRP dan jarak 
tempuh 6MWT, tetapi tidak terdapat hubungan bermakna antara hsTroponin I dengan jarak 
tempuh 6MWT. Namun secara bersama-sama terdapat hubungan bermakna antara kadar 




Ischemic heart disease contributes 
to global burden of disease.1 
Epidemiological characteristic of acute 
myocardial infarction (AMI) has been 
changed dramatically in the last 3-4 
decades.2 In Asia-Pasific, acute coronary 
syndrome (ACS) has become the highest 
number cause of death.3 In the last 3 
decades, AMI management has 
developed and become more advance. 
AMI is necrotic condition in myocardium 
as a result of unstable ischemia 
syndrome. In practice, to establish the 
diagnosis of this disease is based on 
clinical presentation, electrocardiogram, 
biochemical assay, and invasive or 
noninvasive imaging.4 
Biomarker has a role in diagnosis 
and risk stratification in ischemic heart 
disease patient. Troponin is the reference 
biomarker in ACS. Nevertheless there are 
some biomarkerswhich have additional 
value of prognostic information, one of 
them is C-reactive protein (CRP). CRP is 
acute phase reactant to predict 
cardiovascular risk in atherosclerotic 
patient.5 Myocardial ischemia stimulates 
the pro-inflammatory cytokines to produce 
CRP. The result will be remodelling of the 
heart with clinical manifestations of heart 
failure.6 High-sensitivity CRP (hsCRP) 
level has a negative correlation with left 
ventricular ejection fraction (LVEF).7 
Functional capacity in heart 
disease is important. The assessment with 
6-minute walk test (6MWT) can be 
performed to predict cardiovascular events 
in 3 months after ST elevation myocardial 
infarction (STEMI) with fibrinolytic 
therapy.8 There was a significant 
relationship between the 6-minute walk 
distance (6MWD) and the extent of 
extracellular matrix in the LV 
myocardium.9 This study aims to assess 
the correlation between hsCRP and 
hsTroponin I with 6-minute walk distance 
(6MWD) in AMI patients. 






 This study was conducted at Dr. 
Moewardi District General Hospital, 
Surakarta, Indonesia from August to 
September 2018. The inclusion criteria 
were AMI patients who agreed and signed 
the informed consent for this study. 
Patients with chronic kidney disease, liver 
cirrhosis, infection, stroke, previous 
infraction, peripheral artery disease, 
muscle weakness, or died during 
hospitalization were excluded.There were 
40 AMI patients who fulfilled inclusion and 
exclusion criterias. The diagnosis of AMI 
was based on typical chest pain 
characteristics and elevation of cardiac 
marker, with or wihout ST-segment 
changes. The hsCRP and hsTroponin I 
level was examined on admission. The 
Advia 1800 (Siemens) analyzer was used 
to measure the hsCRP level and Mini 
Vidas (Biomérieux) analyzer to measure 
the hsTroponin I level. The 6MWT was 
performed to the subjects according to the 
American Thoracic Society (ATS) 
protocolto get 6MWD, before 
discharged.10 
 The collected data was analyzed 
statistically with SPSS 23.0 software. The 
Shapiro-Wilk test was used to test the 
data normality. The qualitative datawas 
analyzed by the Chi square test or the 
Fisher`s exact test (if not fulfill the criteria 
for Chi square test), while the quantitative 
data was analyzed by the independent t-
test (for normal data distribution) or the 
Mann-Whitney test.The linear regression 
test was used to analyze the correlation 
between hsCRP and hsTroponin I with 
6MWD. To analyze each variable`s 
correlation with 6MWD, Pearson`s product 
moment correlation (for normal data 
distribution) or Spearman`s Rank 
correlation test were performed. The 
receiver operating characteristic (ROC) 
curve was used to determine the cut-off 




 Data with normal distribution was 
presented as mean ± standard deviation 
(SD), the normal distribution transformed 
data was presented as mean (95% 
confidence interval), and the abnormal 
distribution data was presented as median 
(table 1). 
The subjects were divided into 2 
groups based on the mean value of 
6MWD (378 m). There were no significant 
difference of qualitative parameters (table 
2). However, there was a significant 
difference in the EF variable of the 
quantitative parameters analysis (table 3). 
Statistical analysis shows a 
significant negative correlation between 
hsCRP and 6MWD with r value = -0.475, 
but no significant correlation between 
hsTroponin I and 6MWD. In addition, 
hsCRP together with hsTroponin I have a 
significant correlation with 6MWD in AMI 
(table 4).Since hsCRP has the significant 
correlation with 6MWD, then the relative 
risk (RR) is analyzed.  
The hsCRP parameter was divided 
into high and low group based on the 
mean value (0.45 mg/l). The result shows 
RR of 2.53 (95% CI 1.338 – 4.769).It 
means the probability of the subjects with 
hsCRP ≥ 0.45 mg/l to achieve a short 
6MWD is 2.53 times higher than those 
with hsCRP< 0.45 mg/l (table 5). 
The ROC curves were used to 
identify a cut-off point for a short 6MWD 
based on hsCRP and hsTroponin I level. 
The ROC curve for hsCRP (figure 1) 
shows area under curve (AUC) of 0.725 
(moderate), cut-off point level of 0.555 
mg/l, 69.6% sensitivity and 88.2% 
specificity. It means that hsCRP is good 
enough to identify a short 6MWD.  
While the ROC curve for 
hsTroponin I (figure 2) shows AUC of 
0.609 (weak), cut-off point level of 177.05 
ng/l, 65.2% sensitivity and 58.8% 
specificity. It means that hsTroponin I is 










Table 1. Baseline characteristics 
 
Parameters Min – max Mean±SD Median/Mean (95% CI) 
Age (years) 39 – 74 58.05 ± 9.21 - 
BMI 19.1 – 31.1 - 23.15ª 
Onset (hours) 1 – 72 - 4.50ª 
eGFR 10.2 – 130 62.63 ± 25.42 - 
HbA1c(%) 5 – 12.90 - 6.35ª 
Total cholesterol (mg/dl) 83 – 252 180.50 ± 38.13 - 
HDL cholesterol (mg/dl) 22 – 66 40.13 ± 10.03 - 
LDL cholesterol (mg/dl) 55 – 197 126.31 ± 37.09 - 
Triglyceride (mg/dl) 58 – 691 - 136.96(116.81–160.58) ᵇ 
EF (%) 21 – 74 46.99 ± 14.59  
LOS (days) 3 – 11 - 5.77 (5.16 – 6.46) ᵇ 
hsCRP (mg/l) 0.02 – 16.79 - 0.45 (0.26 – 0.79) ᵇ 
6MWD (m) 110 – 585 378.05 ± 90.87  
6MWD: 6-minute walk distance, BMI: body mass index, CI: confidence interval, EF: ejection fraction, eGFR: 
estimated glomerular filtration rate, HDL: high density lipoprotein, hsCRP: high sensitive C-reactive protein, LDL: 
low density lipoprotein, LOS: length of stay, SD: standard deviation 
ª) Abnormal distribution data, presented as median 
ᵇ) Normal distribution transformed data, presented as mean (95% CI) 
 
Table 2. Comparison of qualitative parameters between 2 Groups 
 
Parameters 
6 MWD< 378 m 6 MWD ≥ 378 m 
p value 
n % n % 
Gender 
Male 19 59.4 13 40.6 
0.702 
Female 4 50 4 50 
MI type 




5 62.5 3 36.4 
NSTEMI 14 63.6 8 42.5 
Killip Class 
I 11 42.3 15 57.7 
0,053 
II 7 77.8 2 22.2 
III 4 100 0 0 
IV 1 100 0 0 
DM 
Yes 9 60 6 40 
0.804 
No 14 56 11 44 
Hypertension 
Yes 15 62.5 9 37.5 
0.648 
No 8 50 8 50 
Smoker 
Yes 14 60.9 9 39.1 
0.616 
No 9 52.9 8 47.1 
Dyslipidemia 
Yes 5 55.6 4 44.4 
1.000 
No 18 58.1 13 41.9 
ACEi/ARB 
ACEi 19 54.3 16 45.7 
0.373 
ARB 4 80 1 20 






6 MWD< 378 m 6 MWD ≥ 378 m 
p value 
n % n % 
Beta blocker 
Yes 21 55.3 17 44.7 
0.499 
No 2 100 0 0 
Anticoagulant 
Fondaparinux 10 71.4 4 28.6 
0.351 Enoxaparin 12 52.2 11 47.8 
Heparin 1 33.3 2 66.7 
Heart failure / deterioration of Killip class 
Yes 3 50 3 50 
0.687 
No 20 58.8 14 41.2 
Arrhythmia 
Yes 3 100 0 0 
0.248 




11 57.9 8 42.1 
0.087 
Incomplete 7 87.5 1 12.5 
Complete 5 38.5 8 61.5 
6MWD: 6-minute walk distance, ACEi: angiotensin converting enzyme inhibitor, ARB: angiotensin II 
receptor blocker, DM: diabetes melitus, MI: myocardial infarction, NSTEMI: Non ST-segment 
elevation myocardial infarction, STEMI: ST-segment elevation myocardial infarction 
  
Table 3. Comparison quantitative parameters between 2 Groups 
 
Parameters 
6 MWD< 378 m 6 MWD ≥ 378 m 
p value 
Mean SD Mean SD 
Age (years) 59.95 8.96 55.47 9.15 0.129 
Onset (hours) 9 1 – 72 3 1 – 72 0.466 
BMI 22.40 19.1 – 31.1 23.40 20.7 – 30.1 0.468 
EF (%) 42.3 14.86 53.32 11.89 0.016* 
eGFR 61.61 24.55 64.01 6.60 0.772 
HbA1c (%) 6.50 5.3 – 12.9 6.10 5 – 10 0.143 
Total cholesterol (mg/dl) 177.30 38.33 184.82 38.58 0.544 
HDL cholesterol (mg/dl) 39.96 9.57 40.35 10.92 0.904 
LDL cholesterol (mg/dl) 126.61 36.25 125.47 39.33 0.925 
Triglyceride (mg/dl) 140 63 – 365 117 58 – 691 0.632 
LOS (days) 6.30 1.94 5.88 2.39 0.542 
6MWD: 6-minute walk distance, BMI: body mass index, EF: ejection fraction, eGFR: estimated glomerular 
filtration rate, HDL: high density lipoprotein, hsCRP: high sensitive C-reactive protein, LDL: low density 
lipoprotein, LOS: length of stay, SD: standard deviation  
*) Significant if p value < 0.05 
 




Correlation  p value  
hsCRP with 6MWD r = -0.475 0.002* 
hsTroponin I with 6MWD r = -0.048 0.769 
hsCRP and hsTroponin I with 6MWD R = 0.491 0.006* 
6MWD: 6-minute walk distance, hs: high-sensitive, CRP: C-reactive protein 
*) Significant if p value < 0.01 
 







Table 5. Relative risk for short  6MWD in high and low hsCRP 
Parameters 6MWD <378 m 6MWD ≥ 378 m p value RR (95% CI) 
hsCRP ≥ 0.45 mg/l 16 (69.6%) 3 (17.6%) 
0.001* 
2.53 (1.338 – 
4.769) hsCRP< 0.45 mg/l 7 (30.4%) 14 (82.4%) 
6MWD: 6-minute walk distance, hsCRP: high-sensitive C-reactive protein 




Figure 1. ROC curve for hsCRP and 6MWD 
6MWD: 6-minute walk distance, AUC: area under the curve, hsCRP: high sensitive C-reactive protein, 
ROC: receiver operating characteristic 
 
 






Figure 2. ROC curve for hsTroponin I and 6MWD 





 This study shows a significant 
negative correlation for hsCRP and 
6MWD. It means if hsCRP level is high 
then 6MWD will be short, and vice versa. 
Furthermore, hsCRP together with 
hsTroponin I has a significant correlation 
with 6MWD. While hsTroponin I has no 
significant correlation with 6MWD. It might 
be caused by the different MI onset of the 
subjects. The troponin I reach the peak at 
12-36 hours after MI, then it will decline.11 
 Acute myocardial infarction 
initiates danger-associated mollecular 
patterns (DAMPs) production, which 
activates complement cascade and 
stimulates toll-like receptors (TLRs), and 
eventually activates NF-kB. It will cause 
the release of various pro-inflammatory 
mediators, such as IL-1, IL-6 and TNF-α. 
The pro-inflammatory mediators will 
induce inflammatory cell recruitment into 
the infarcted zone, and increase the pro-
inflammatory response after AMI. IL-6 will 
regulates the synthesis of CRP, while 
TNF-α will stimulate matrix 
metalloproteinase (MMP) production.12 
 Troponins are cardiac proteins, 
which are important for actin and myosin 
interaction, modulating sarcomeric 
contractile function in response to 
cytosolic calcium and protein 
phosphorylation.5 Disturbance of myocyte 
contractility could be a cause of ventricular 
dysfunction in cardiac remodeling.13In the 
infarcted myocardium, the 
polymorphonuclear leucocytes have some 
roles, such as phagocytosis of the necrotic 
tissue, extracellular matrix degradation 
through MMP release, and the release of 
reactive oxygen species (ROS). Those will 
lead to the left ventricular remodelling, 
which will result on the short 6MWD.9 
 A study involving 118 patients with 
AMI onset < 6 hours, examined CRP level 
on admission. The early CRP level was 
associated with Killip class, LVEF, number 
of stenotic arteries, and cardiovascular 
events 1 month and 1 year after 
infarction.14  





The increase of CRP level on early 
infarction also has association with the 
existence and the mitral regurgitation 
severity, and with the diastolic dysfunction. 
This indicates the association of 
inflammatory and ventricular remodelling 
process.15 The extracellular matrix 
components will extent myocardial 
stiffness, and contribute to the reduction of 
LV compliance during diastole and the 
increase of LV diastolic filling pressure.16 
A study in patients with LVEF 15-45% 
showed that their 6MWD was shorter than 
normal person.17 
This study has some limitations. 
First, this is a single center study, so the 
result may not present the condition in the 
other region. Second, the hsCRP and 
hsTroponin I level was based on 1 time 
sampling (on admission). The subjects 
came with different onset of MI, so their 
hsCRP and hsTroponin level may be 
beyond the peak level and may have 
decreased. A multicenter study should be 
done to MI subjects with onset ≤ 2 days, 
so the result will reflect more about the 
early condition of the disease. 
 
CONCLUSION 
 This study showed a significant 
negative correlation between hsCRP and 
6MWD in AMI patients. Furthermore, 
hsCRP together with hsTroponin I has a 
significant correlation with 6MWD. 
However, there was no significant 
correlation between hsTroponin I and 
6MWD in AMI patients.  
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